Biocure Technology Inc. (BICTF)
Biocure Technology Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $379,088. On trailing twelve-month figures it carries a trailing P/E of -0.08, a net margin of 0.0%. Its beta of 3.78 implies it has historically moved more than the broad market.
Biocure Technology Inc., along with its subsidiary, is dedicated to the development and market introduction of biopharmaceutical technologies, particularly those leveraging recombinant proteins and ranibizumab. The company's therapeutic pipeline features Interferons-ß, which are being advanced for the treatment of multiple sclerosis. They are also developing Ranibizumab, a monoclonal antibody fragment designed to address macular degeneration and a related ocular condition known as macular edema. Furthermore, Biocure is progressing Filgrastim, a treatment for neutropenia—a deficiency of white blood cells often resulting from cancer, bone marrow transplantation, chemotherapy, or other health issues. Beyond these, Biocure Technology is actively engaged in the research and development of innovative CAR T Cell therapy, intended to pinpoint and destroy cancer cells. Their investigative efforts also encompass a vaccine for foot and mouth disease and a variety of hair growth solutions. Established in 2005, the company's main operations are situated in Vancouver, Canada.
Biocure Technology Inc. is most often compared with the following Healthcare names: